Tumor cells in chronic lymphocytic leukemia accumulate in the periphery through the proliferation of a minority of cells in lymph nodes. The proliferative and survival signals in these proliferation centers include interactions with T lymphocytes expressing CD40 ligand. We have demonstrated that the low toxicity combination of bezafibrate and medroxyprogesterone acetate induces mitochondrial superoxide-mediated apoptosis of non-CD40-liganded cells but not of cells exposed to CD40 ligand. Here, we assessed the ability of dasatinib and lycorine to restore bezafibrate-and medroxyprogesterone acetate-induced apoptosis in cells exposed to CD40 ligand. In parallel experiments we compared the ability of dasatinib to induce apoptosis of cells co-treated with fludarabine.
Introduction
Chronic lymphocytic leukemia (CLL) is a disease of neoplastic B cells characterized by the progressive accumulation of CD5 + B lymphocytes in the peripheral blood, bone marrow and secondary lymphoid organs. [1] [2] [3] [4] In the western world it is the most common form of adult leukemia and has a widely variable clinical course with many patients never requiring therapy. There are 22-30/100,000 new cases per year worldwide and the majority of patients are over 65 years old. 5 According to recent Surveillance, Epidemiology and End Results the median age at diagnosis is 72 years. 6 In younger patients, the current front-line therapy is a combination of fludarabine, cyclophosphamide and rituximab 7 but this regimen is associated with significant toxicity for elderly patients. CLL remains incurable for the majority of patients who become refractory to chemotherapy 6, 8, 9 and there is a need to develop less toxic and novel therapies that can overcome drug resistance. 8 The tumor microenvironment, in particular the lymph nodes, has been shown to be both the center for CLL cell proliferation and to protect cells against chemotherapeutics. 10 The lymph node is rich in T cells that express CD40 ligand (CD40L) and engage CLL cells via CD40 to stimulate proliferation in proliferation centers and protect against apoptotic signals. Histopathology has confirmed that within the proliferation centers, proliferating CLL cells are directly exposed to CD40L signals. 11 Furthermore, CLL cells are protected from spontaneous apoptosis in vitro when co-cultured with autologous T cells 12 and many studies, including our own, have demonstrated that CLL cells are protected from drug-induced apoptosis by culture with CD40L and interleukin-4. [13] [14] [15] [16] Therapies that overcome this protective mechanism within proliferation centers, while also targeting the circulating neoplastic cells, are likely to provide better response rates and reduce the rate of relapse. Encouragingly, Hallaert et al. 17 recently found that the protective effects of CD40L could be overcome by the use of the c-Abl kinase inhibitor, dasatinib. It was reported that this was due to a reduction in anti-apoptotic proteins and it was proposed that this agent could successfully sensitize CLL cells within the lymph nodes to chemotherapeutics such as fludarabine. However, the CD40L signal was not provided continuously and the apoptosis associated with dasatinib treatment was only apparent following removal of CD40L. It cannot, therefore, be categorically concluded that dasatinib would be able to overcome CD40L in vivo and sensitize CLL cells to therapeutics. In addition, it is questionable whether the dose of 100 μM fludarabine is clinically achievable, since the reported peak concentration of fludarabine in lymphocytes and plasma is between 3 and 19 μM. [18] [19] [20] We have investigated, in vitro, the potential of combining bezafibrate and medroxyprogesterone acetate (MPA) against CLL, acute myeloid leukemia and Burkitt's lymphoma, 15, 21, 22 and also conducted a phase II clinical study of the combination (bezafibrate + MPA) in acute myeloid leukemia. 23 This phase II study showed that the combination was of clinical benefit and did not have associated hematologic or systemic toxicities. 23 These findings indicated the potential benefit of exploiting such therapy in CLL patients, especially those who are frail and not able to endure more toxic regimens. However, although we demonstrated that bezafibrate + MPA could induce apoptosis of non-CD40L-stimulated CLL cells and reduce their CD40L-induced proliferation, 15 we did not observe that combined bezafibrate + MPA provoked apoptosis in CD40L-protected cells. The lack of apoptosis in the presence of CD40L was associated with protection against bezafibrate + MPA-induced mitochondrial superoxide production. In this study we examined whether the addition of a third agent could overcome the protective signal provided by CD40L and lead to the restoration of mitochondrial superoxide accumulation and the successful apoptosis of CLL cells within this environment.
Mankind has always used plants as a source of natural medicines. Indeed, extracts from the Narcissus genus of Amaryllidaceae were documented to have been used as cancer therapy by Hippocrates in the 4 th century BC. 24 In recent decades, the scientific community has investigated the therapeutic use of numerous plant-derived compounds and many have been studied as anti-leukemia therapies. These include PEP005, derived from Euphorbia peplus, in the treatment of acute myeloid leukemia, 25 jasmonates, plant hormones found in all plants, in acute myeloid leukemia, CLL and B-cell lymphoma, [26] [27] [28] [29] and pancratistatin and lycorine from the Amaryllidaceae family in acute myeloid leukemia and acute promyelocytic leukemia. [30] [31] [32] Lycorine is the most abundant of all the Amaryllidaceae alkaloids and has wide ranging biological activities. Studies this century have indicated that lycorine interferes with replication of the polio, small pox and SARS viruses, [33] [34] [35] [36] has anti-fungal activities 37 and is anti-parasitic, including against malaria. 38 In the last decade research has focused on the potential use of this compound to treat cells resistant to apoptotic stimuli, 39 including leukemic cells. 24, [30] [31] [32] 36 In vitro studies in such settings have shown that lycorine can induce apoptosis, specifically targeted against malignant cells. 31 Its potential use as a therapeutic agent has recently led to studies into the production of the synthetic compound, 40, 41 highlighting it as a potential lead for drug development. 24, 42 In this study we investigated the potential of combining lycorine with bezafibrate + MPA to elicit an apoptotic response in the presence of CD40L and assessed the correlation between induced apoptosis and the generation of mitochondrial superoxide. We compared our findings of those of Hallaert et al. and looked at the importance of the continual provision of CD40L to truly mimic the lymph node environment.
Design and Methods

Patients and donors
The CLL cells used were from unselected patients diagnosed with B-cell CLL according to standard morphological, immunophenotypic and clinical criteria 43 and attending the outpatient clinic at Birmingham Heartlands Hospital, UK. Patients provided informed written consent to the study which had received local ethical approval. Normal donors were recruited following informed consent. Primary mononuclear cells were prepared using Ficoll Paque-Plus (Anachem) as previously described.
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Cell culture using L cells
Murine L cells stably transfected with plasmids encoding CD40L, as described previously, 44 as well as non-transfected L cells (both a gift from Prof. John Gordon) were maintained, treated with mitomyocin C (Sigma) and seeded for co-culture as described previously. 15 Mononuclear cells were seeded on to the stromal L cells, at a ratio of 10:1 in RPMI 1640 with 10% fetal bovine serum, 1% penicillin-streptomycin and 1 ng/mL interleukin-4 (R&D systems), while treated as described in the text.
Removal of chronic lymphocytic leukemia cells from the stromal support
CLL cells were removed from the stroma as described previously. 15 The CLL cells were either analyzed immediately following removal or washed in warm phosphate-buffered saline, and resuspended in 200 μL RPMI, supplemented as before, with 1 ng/mL interleukin-4 and the appropriate treatments and cultured for a further 24 h before analysis. Immediately prior to harvest cultures were viewed using an inverted microscope to ensure the integrity of the stromal support following the treatments.
Treatments
Stocks (1000 x) of 0.5 M bezafibrate in dimethylsulfoxide, 5 mM MPA in ethanol, 10 mM fludarabine, a 10,000 x stock of 100 mM lycorine (all from Sigma, Poole, UK) in dimethylsulfoxide and 50 mM dasatinib (LC Laboratories, MA, USA) in dimethylsulfoxide were stored at -20ºC. All treatments were set up in triplicate with controls containing the highest concentration of carrier solvent used in the corresponding treatments.
Assessment of apoptosis by annexin V
All analyses were carried out by flow cytometry on a BD FACS Calibur utilizing Cell Quest Pro software (BD). Following treatment, CLL cells from triplicate wells were pooled and incubated with annexin V and propidium iodide from an annexin V FITC kit (BD, Oxford, UK), according to manufacturer's instructions.
Assessment of accumulation of mitochondrial superoxide
MitoSOX Red (Molecular Probe) was used to assess the presence of mitochondrial superoxide in pooled triplicate wells, as described previously.
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Assessment of protein expression
CLL cells were cultured in 6-well plates with non-CD40L stroma or CD40L stroma and were treated for 24 h or 48 h, respectively. The cells were removed from the stromal support as described above, washed once in phosphate-buffered saline and the pellet snap-frozen in liquid nitrogen. Whole cell pellets were lysed in 1x Laemmli dye loading buffer and boiled for 10 min. CLL lysates, together with the lysate from Huh cells (used as a positive control), were separated by 12.5% sodium-dodecylsulfate polyacrylamide gel electrophoresis prior to semi-dry transfer to polyvinylidene fluoride Immobilon-P membrane (Millipore Corp, Watford, Herts., UK). Membranes were blocked for 1 h with 5% (w/v) non-fat milk powder (Marvel, Wisbech, Cambs., UK) in Tris-buffered saline Tween-20 (TBS-T), briefly washed and probed with a 1 in 1000 dilution of anti-SODII antibody (BD) in 5% (w/v) non-fat milk powder in Tris-buffered saline Tween-20 overnight. Following washing in TBS-T, membranes were probed with anti-mouse antibody (Sigma) diluted 1 in 1000 as above, for 45 min. The signal was developed using Supersignal West Pico Chemiluminescent substrate (Pierce, Cramlington, Northumberland, UK). Autorads were exposed for 1 min. Equal loading was assessed using anti-β-actin antibody (Sigma) diluted 1 in 25 000 for 45 min and an antimouse secondary antibody diluted 1 in 25 000 for 45 min and developed as above.
Statistical analysis
Data are reported as mean values and their standard deviation or standard error of the mean as stated. P values were calculated using the non-parametric Wilcoxon's test in SPSS version 14.
Results
When the protective CD40-ligand is maintained, the dasatinib plus fludarabine combination no longer induces apoptosis of chronic lymphocytic leukemia cells
Using 5 μM of fludarabine, a dose that more closely reflects an achievable plasma and intra-lymphocyte concentration [18] [19] [20] we were able to reproduce the observations reported by Hallaert et al. that dasatinib did not induce apoptosis alone, but that the combination of dasatinib and fludarabine did, following continuous drug exposure for 72 h with the final 24 h of treatment being in the absence of CD40L ( Figure 1A ). However, using this methodology bezafibrate + MPA also induced apoptosis and to a similar level as dasatinib + fludarabine (P=0.51). In contrast, and as we described previously, 15 
Lycorine alone does not induce apoptosis of primary chronic lymphocytic leukemia cells in the presence of CD40-ligand
We hypothesized that the addition of an appropriate third agent may be able to overcome the protective effects of CD40L against bezafibrate + MPA, and result in the desired induction of apoptosis. Following recent publications on the use of lycorine in causing apoptosis of acute promyelocytic leukemia and acute myeloid leukemia cell lines, 30, 36, 45 we investigated whether this agent has potential in CLL. A dose titration of lycorine, starting at the highest dose shown to be effective against HL-60 and K562 cells by Lui et al., 32 was conducted in CLL samples, from six patients, in the presence of CD40L. None of the doses tested induced significant apoptosis in primary CLL cells (P=0.1 for all treatments) ( Figure 2B ). However, the addition of lycorine to bezafibrate + MPA proved to be effective at inducing the death of CLL cells even when continuously exposed to CD40L (Figure 2A and B) . Even the lowest dose tested (0.6 μM) combined with bezafibrate + MPA potentiated apoptosis (36%) compared to that of cells treated with bezafibrate + MPA alone (P=0.017). The pro-apoptotic effect of bezafibrate + MPA + lycorine reached a plateau at doses of lycorine above 1.25 μM, with no significant increases in the level of apoptosis (P£0.1 for all higher doses tested).
Mitochondrial superoxide is produced in response to bezafibrate plus medroxyprogesterone plus lycorine
Our previous study showed that bezafibrate + MPAinduced apoptosis in the absence of CD40L was associatLyocrine sensitizes CD40L-protected CLL cells haematologica | 2010; 95 (11) ed with the production of reactive oxygen species and mitochondrial superoxide. In contrast, the survival of bezafibrate + MPA-treated cells in the presence of CD40L was associated with the induction of reactive oxygen species but not mitochondrial superoxide. We argued that CD40L protects against bezafibrate + MPA-induced apoptosis by protecting against or countering mitochondrial superoxide production. We tested whether the capacity of lycorine to potentiate the ability of bezafibrate + MPA to induce apoptosis in cells exposed to CD40L was associated with the restoration of the mitochondrial superoxide response at 48 h. Consistent with the lack of cell death induced by lycorine alone, by itself this agent did not induce mitochondrial superoxide production (P£0.1 for all) ( Figure 3A and B) . A small increase in mitochondrial superoxide was observed in response to 10 μM lycorine; however, even at this dose, the amount of mitochondrial superoxide produced was no more than that produced by bezafibrate + MPA alone ( Figure 3A and B) . In contrast, the combination of bezafibrate + MPA + lycorine induced substantial, lycorine-dose-dependent increases in mitochondrial superoxide, with bezafibrate + MPA + 1.25 μM lycorine producing the highest level of mitochondrial superoxide (P=0.004) ( Figure 3B) . Importantly, the lycorine-mitochondrial superoxide dose-response mirrored the induction of apoptosis as measured by annexin V staining and cell viability ( Figures 2B, 3C and 3D ). Direct comparison of total mitochondrial superoxide against viable events ( Figure 4A ) and annexin V staining against mitochondrial superoxide ( Figure 4B ) further demonstrated that an increase in mitochondrial superoxide was
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haematologica | 2010; 95(11) directly associated with the loss of viability and apoptosis. These data on two measures of apoptosis compared with mitochondrial superoxide production indicate that the apoptosis caused by the combination of bezafibrate + MPA + lycorine is likely to be due to restored accumulation of mitochondrial superoxide within the treated cells. Previous studies demonstrated that transcription of the mitochondrial superoxide antioxidant manganese superoxide dismutase is up-regulated in cells exposed to tumor necrosis factor-α. 46 As CD40 and its ligand are members of the tumor necrosis factor family, we hypothesized that CLL cells exposed to CD40L may also up-regulate manganese superoxide dismutase and, thereby, overcome the pro-apoptotic effects exerted by bezafibrate + MPA. Alternatively, bezafibrate + MPA may induce apoptosis in the absence of CD40L by down-regulating manganese superoxide dismutase and this action may be counteracted by CD40L; according to this hypothesis, lycorine, in the presence of CD40L, would reverse this down-regulation. However western blot analysis of protein expression revealed that CD40L did not up-regulate manganese superoxide dismutase ( Figure 4C ). Further, neither in the absence nor in the presence of CD40L was bezafibrate + MPA, lycorine or the combination able to induce downregulation of this protein ( Figure 4C ).
Lycorine only modestly potentiates bezafibrate-plus medroxyprogesterone acetate-induced apoptosis in the absence of CD40-ligand
We next investigated the effects of lycorine on CLL cells in the absence of CD40L. Lycorine alone induced a modest dose-dependant increase in apoptosis ( Figure 5 ). Even at the highest dose tested lycorine was no better at inducing apoptosis than bezafibrate + MPA (P=0.83). When combined with bezafibrate + MPA, lycorine did increase the amount of apoptosis observed; however, the effect was less striking than that detected in the presence of CD40L. The bezafibrate plus medroxyprogesterone acetate plus lycorine combination, but not dasatinib plus fludarabine, is selective for chronic lymphocytic leukemia cells
In our previous study, 15 we demonstrated that bezafibrate + MPA had minimal effects on normal B cells, indicating tumor cell selectivity. Here we tested the effect of dasatinib + fludarabine on normal peripheral blood mononuclear cell apoptosis and compared the response with that of bezafibrate + MPA with and without lycorine. Neither bezafibrate + MPA, 1.25 μM lycorine, or the triple combination significantly increased apoptosis of peripheral blood mononuclear cells either in the presence or the absence of CD40L (P£0.1 for all) (Figure 6 ). The combination of bezafibrate + MPA +10 μM lycorine induced some apoptosis (data not shown); however, since the most significant anti-CLL activity of lycorine + bezafibrate + MPA was observed at a dose of 1.25 μM lycorine we suggest that a dose of 10 μM would not be used as CLL therapy. Dasatinib induced a small amount of peripheral blood mononuclear cell apoptosis (P=0.048) ( Figure 6 ). In contrast, fludarabine increased apoptosis of peripheral blood mononuclear cells cultured both with and without CD40L. Furthermore, there was a trend to significantly increased apoptosis for the combination of dasatinib + fludarabine compared to control (P=0.001) ( Figure 6 ).
Discussion
Despite many developments in the treatment of CLL and improved response rates, the disease remains incurable and overcoming chemoresistance without high levels of toxicity is a priority. Migration of circulating CLL cells to lymph nodes provides the cells with survival signals from CD40L, causing the development of pro-survival niches that are widely believed to be the source of therapy resistance and relapse. 17, 47 Chemoresistance has been reported in CLL cells that have been exposed to CD40L 13, 14 and Vogler et al. recently demonstrated that CLL cells exposed to CD40L have 1000-fold increased resistance to the novel therapeutic ABT-737. 16 It appears, therefore, that CD40L can protect CLL cells against a variety of potential treatments. Thus it could be speculated that CLL cells effectively 'seek cover' from anti-neoplastic therapy by exploiting CD40L within the lymph nodes. We have recently shown that bezafibrate + MPA can induce apoptosis of circulating CLL cells, while significantly reducing the proliferative capabilities of CLL cells when engaged with CD40L. 15 However, the lack of apoptosis within an environment mimicking the lymph node led to our search for a third agent to combine with bezafibrate + MPA with the aim of exerting apoptosis both in the absence and presence of CD40L. The recent study by Hallaert et al. identified the possibility of using dasatinib as an agent to sensitize CLL cells to other therapies. 17 However, the experiments herein have demonstrated that the ability of dasatinib to promote apoptosis requires that the cells are no longer perceiving protective signals from CD40L. Thus, the implications of the study of Hallaert et al. are not dissimilar to those of Veldurthy et al. 48 and Amrein et al. 49 who demonstrated dasatinib potentiation of fludarabineinduced apoptosis in CLL cells not provided with CD40L.
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haematologica | 2010; 95(11) Furthermore, in this scenario, the actions of combined dasatinib + fludarabine were no greater than those of bezafibrate + MPA. However, lycorine was able to sensitize CLL cells to bezafibrate + MPA-induced apoptosis in the continuous presence of CD40L. Furthermore, the ability to do so was associated with restored accumulation of mitochondrial superoxide in response to bezafibrate + MPA. This would indicate that either lycorine reinstates the capacity of bezafibrate + MPA to induce mitochondrial superoxide in CD40L-stimulated cells or interferes with the CD40L-mediated clearance of mitochondrial superoxide. This is the first study to show a correlation between the generation of mitochondrial superoxide and cell death in CLL.
We postulated that a possible mechanism of action of lycorine and/or bezafibrate + MPA could be disrupted regulation of the mitochondrial superoxide manganese superoxide dismutase. However, we found that CD40L does not induce up-reglaution of this superoxide dismutase, and that the agents studied were not interfering with this pathway. Nonetheless, the possibility that lycorine exerts its effects via mitochondrial mechanisms is supported by studies in Saccharomyces cerevisiae, which have demonstrated that cells lacking mitochondrial DNA are resistant to lycorine. 50 Elderly CLL patients are commonly excluded from clinical trials because of their susceptibility to the development of cytopenia and infections and in younger patients there is an inevitable development of chemoresistance to conventional agents. Thus more targeted therapies are urgently required. Studies on mononuclear cells isolated from normal donors demonstrated that the combination of dasatinib + fludarabine caused significant apoptosis, whereas the combination of bezafibrate + MPA + lycorine left the normal cells relatively unaffected, further highlighting the potential of our approach.
Currently, many plant compounds are being investigated with the intention of gaining FDA approval for their therapeutic use. Recently, the prescription drug Reminyl was approved for the treatment of Alzheimer's disease. The active ingredient of this compound is the alkaloid galanthamine isolated from another member of the Amaryllidaceae family. 42, 51 Therefore a precedent has been set for the use of this group of agents in the treatment of diseases. Lycorine has been identified as a novel lead for anticancer drug design 24, 39 and Jones et al. have published the first successful study of the synthesis of the framework of one of lycorine's sister compounds. 40 Thus, the concept of lycorine ultimately being synthesized successfully and gaining FDA approval for therapeutic use is a real possibility. Nonetheless the time scale and cost of developing new drugs are limiting and in addition the in vivo toxicity of lycorine is as yet unknown and will have to be determined prior to possible trials in combination with bezafibrate + MPA.
In conclusion, our studies continue to indicate bezafibrate + MPA as potential therapies for CLL. Importantly this study provides the proof of principle that strategies using bezafibrate + MPA can be developed with the potential to target cells both in the periphery and in the protective lymph node environment and demonstrates that the generation of mitochondrial superoxide is critical for apoptosis. It remains possible that other already available drugs could also target the cells within the lymph node as effectively as lycorine. Unfortunately, these do not appear to include dasatinib but screens of other agents could yield promising results. Our data would suggest that agents targeting mitochondria may be strong candidates. We, therefore, propose that rational drug screening for a third agent should be based on the generation of mitochondrial superoxide as measured by MitoSox. If a suitable agent could be found this would be the most expedient way to develop the regime as a clinically viable treatment. 
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